The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy
Rev. Soc. Bras. Med. Trop
; 47(4): 528-532, Jul-Aug/2014. tab, graf
Article
in En
| LILACS
| ID: lil-722305
Responsible library:
BR1.1
ABSTRACT
Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfill criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.
Key words
Full text:
1
Index:
LILACS
Main subject:
Paraparesis, Tropical Spastic
/
Botulinum Toxins, Type A
/
Urinary Bladder, Overactive
/
Acetylcholine Release Inhibitors
Type of study:
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
MEDICINA TROPICAL
Year:
2014
Type:
Article